Patent Application
20080085852
Peptides of general formula XIKVAV form a chemotactic region in laminin, i.e. a cell attraction region. This is the reason why these peptides promote cell adhesion, growth and migration, thus regenerating the basal lamina. Angiogenesis stimulation (formation of new blood vessels) properties, which promote the proliferation and differentiation of endothelial cells, are also known in these peptides [Journal of Cellular Physiol. 1992 December; 153(3):614-25].
The interactions between peptides of form XIKVAV and receptor integrins are known and their use is described in patent number EP 1 325 739 [“Liposomes encapsulating anticancer drugs and the use thereof in the treatment of malignant tumors”] where the over-expression of laminin receptors in the membranes of tumor cells is used to steer towards the latter liposomes coated with XIKVAV peptides containing anti-tumor agents.
It has now been determined that XIKVAV peptides have different cosmetic application functions at the level of cutaneous cells, which are the following:
A cosmetic composition including peptides of general formula XIKVAV capable of increasing the firmness of the skin, thus delaying the aging thereof, has been designed in the present invention.
Assays have been carried out to quantify the increase of cell adhesion of keratinocytes and fibroblasts, as well as the generation of integrins, laminins, etc.
In summary, XIKVAV peptides are capable of favoring keratinocyte adhesion by themselves and stimulating the synthesis by fibroblasts of laminin V and α6 integrin (bioadhesion peptides), both of which are involved with the hemidesmosomes which are essential structures for the dermal-epidermal junction.
Likewise, the aforementioned microcirculation stimulation together with the good condition of the basement membrane will aid in the suitable transport of oxygen and metabolites, as well as in the elimination of excretion products, thus improving the functional capacity of epidermal cells and at the same time their resistance and firmness.
Therefore, the use of XIKVAV peptides incorporated in a cosmetic composition of topical application has a direct effect on the prevention of skin aging, delaying the loss of contact between the dermis and the epidermis and preventing the structural and functional changes forming part of the aging process.
Therefore, according to a first aspect of the invention, the latter relates to the use of peptides of general formula XIKVAV (see
Preferably, in the peptides of general formula XIKVAV, X is hydrogen, serine, palmitoyl or decanoyl and Y can be amino, hydroxyl or thiol, all of them substituted or non-substituted with fatty acids.
Preferably, in the peptides of general formula XIKVAV, X is serine and Y is hydroxyl, i.e. the SIKVAV peptide.
Preferably, in the peptides of general formula XIKVAV, X is hydrogen and Y is hydroxyl, i.e. the IKVAV peptide.
Preferably, the cutaneous cells in which bioadhesion is stimulated are keratinocytes and the bioadhesion peptides are a6 integrin and laminin V.
According to a second aspect of the invention, the latter relates to a cosmetic composition comprising, in a cosmetically acceptable medium, a cosmetically-effective quantity of peptides having general formula XIKVAV for the stimulation of cutaneous cell bioadhesion by increasing the expression of bioadhesion peptides.
Said composition is preferably of dermal application.
According to a preferred embodiment, said composition increases the firmness of the skin and this effect is caused by increasing the adhesion of cutaneous cells in relation to one another and the basal lamina.
In the present invention, the XIKVAV peptides (see
In the present invention, the XIKVAV peptides (see
The preferred excipients are those commonly used in cosmetics: water, alcohols, lecithins, natural or artificial polymers, surfactants and active surface agents, preservatives, etc.
The preferred cosmetic forms are those commonly used: creams, lotions, emulsions, shampoos, serums, gels, etc.
According to a preferred embodiment, the composition comprises the following ingredients in the following percentages by weight:
Other active ingredients used as part of the cosmetic composition can be vitamins, natural extracts, ferments and other common ingredients for the various uses of cosmetic formulations: anti-aging, anti-cellulite, moisturizing, regenerating, revitalizing ingredients, etc.
According to another aspect, the present invention relates to the use of peptides of general formula XIKVAV in the preparation of a cosmetic composition increasing the firmness of the skin.
Since cells use integrins to recognize laminins, and laminins bind cells through integrins, the cosmetic composition according to the present invention will enhance cell adhesion and their binding to the basement membrane because XIKVAV peptides are capable of increasing the production of integrins and laminins and are compatible for being able to be used as ingredients in a cosmetic composition.
As will be reflected below in the examples, assays have been carried out in which the adhesive effect in skin cells, obtained thanks to the presence of peptides of general formula XIKVAV, as well as an increase in cell proliferation is observed.
Therefore, this increase of cell proliferation together with the adhesive effect obtained with the use of peptides of general formula XIKVAV allow as a result obtaining a more compact epidermis, preventing the loss of firmness which is very characteristic of skin aging.
Another characteristic of aged skin is the loss of contact between cells, giving rise to a lack of nutrition and changes in the skin such as dryness, yellowish complexion and loss of functionality.
These signs of aging can be combated using the cosmetic composition developed according to the present invention including peptides of general formula XIKVAV.
The experiments set forth below are described as a support of particular aspects of the present invention and in no case do they limit the scope thereof.
Immunostaining assays have been carried out in human fibroblasts and keratinocytes in order to determine if SIKVAV has the ability to enhance the expression of α6 integrin and laminin V (
Given that cells use integrins to recognize laminins, and laminins bind cells with the basement membrane through integrins, a peptide which is able to increase the production of integrins and laminins will enhance cell adhesion and their binding to the basement membrane.
The assay uses a primary (monoclonal) antibody binding to the protein which is intended to be detected (integrin or laminin), and a secondary (polyclonal) antibody binding to the complex between the protein and the primary antibody. The secondary antibody is coupled to a fluorescent compound (FITC-Fluorescein Isothiocyanate).
FITC is illuminated with filtered light at 495 nm (absorption wavelength) and the light emitted by the dye is detected at 528 nm (emission wavelength).
These aspects are observed in
The expression of α6 integrin in human fibroblasts that have not been treated with SIKVAV can be observed by immunofluorescence emission in
The difference in the expression of laminin in the presence and absence of SIKVAV has been identified in this same assay.
This difference of expression can be observed in
As a conclusion, a significant increase of laminin V and α6 integrin can be observed in fibroblasts treated with SIKVAV but not in keratinocytes. No variation in the production of beta 1 integrin was not detected either.
The adhesion process at a cellular level has been determined by means of a in vitro fibroblast culture in the second embodiment assay.
This fact is shown in
In addition to promoting cell adhesion and migration, the cosmetic preparation with SIKVAV favors the formation of blood vessels, improving microcirculation.
This embodiment shows the in vitro evaluation of the cell adhesion of keratinocytes to peptides of general formula XIKVAV and the comparative evaluation between them.
This embodiment shows how cutaneous cell adhesion increases in the presence of XIKVAV peptides and the comparison of the different variants thereof: SIKVAV, IKVAV, Pal-IKVAV, SIKVAV-OH and SIKVAV-NH2 (see
The cell cultures used in the following example are human epidermal keratinocytes (HEKa) in the presence of specific growth factors of keratinocytes.
First, 96 microwells are placed in a plate, they are coated with 50 μL of a peptide of general formula XIKVAV (0.5-250 μg/ml per microwell) in distilled water and dried overnight at room temperature.
On the other hand, control assays are carried out with microwells coated with 40 μM of BSA (bovine serum albumin) so as to evaluate non-specific cell adhesion.
All the microwells have been washed with 200 μL of PBS (phosphate buffered saline) and blocked for 1 hour with 1% BSA in PBS at 37° C.
Trypsin was added to human cutaneous keratinocytes, and they were marked for 30 minutes at 37° C. in calcein-AM at a concentration of 5 μM and they were finally washed three times in Epilife® medium.
The marked cells (4.5×104/microwell) were added to the plate previously coated with the XIKVAV peptide and were incubated for 2 hours at 37° C. in an atmosphere humidified with 5% CO2.
The cell adhesion was assessed by the measurement of calcein fluorescence before and after the washing.
The percentage of cell adhesion was determined by dividing the fluorescence of adhered cells by the total fluorescence of cells added to each microwell.
The cell adhesion promoted by the XIKVAV peptides was calculated with respect to the non-specific adhesion of the cells to BSA.
The results show that the XIKVAV peptides are capable of promoting keratinocyte adhesion in a dose-dependent manner (see
The cell fixing caused by XIKVAV peptides was 65% with respect to the non-specific adhesion at the highest concentration studied.
These results show that XIKVAV peptides are recognized by specialized receptors in the cell surface.
These findings suggest that the peptides of general formula XIKVAV are good candidates to form part of cosmetic formulations for restructuring and increasing the firmness of the skin.
If
If the extrapolated results of
| Number | Date | Country | Kind |
|---|---|---|---|
| P200401018 | Apr 2004 | ES | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/ES05/00175 | 4/5/2005 | WO | 00 | 10/17/2007 |
